A further question arising from this study is whether the reprogramming capacity of cutaneous SCs remains the same, and how the associated biomarkers (e.g. SOX10) are involved in nSCs following nerve damage caused by hyperglycaemia. The gene discussed is SOX10; the disease is Hyperglycemia.